Positives

• An NMOSD patient on the twice-yearly maintenance schedule reported a 77% relative reduction in attack risk and significantly fewer hospitalizations compared with prior therapies PMC.
  
  
• A patient who had failed rituximab said deeper depletion that includes plasmablasts was the deciding factor, and she described feeling "more like myself" after subsequent infusions Drugs.com.
  
  

Negatives

• A patient reported headache, fatigue, and weakness after her first infusion, with effects lasting several days before subsiding PMC.
  
  
• Recurrent urinary tract infections and joint pain were the most common ongoing complaints from users on long-term therapy Drugs.com.
  
  

Hurdles & Side Effects

• A patient with autoimmune-pattern Long COVID found that prescribers refused to consider the drug outside its NMOSD or generalized myasthenia gravis labels Drugs.com.
  
  
• A user described the loading regimen of two infusions two weeks apart followed by a six-month maintenance gap as logistically demanding to schedule around an infusion suite Drugs.com.